PMID- 23909993
OWN - NLM
STAT- MEDLINE
DCOM- 20140716
LR  - 20151119
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 169
IP  - 5
DP  - 2013 Nov
TI  - Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 
      119 patients at a single Spanish centre.
PG  - 1141-7
LID - 10.1111/bjd.12543 [doi]
AB  - BACKGROUND: Patients with moderate-to-severe psoriasis treated with adalimumab in 
      daily clinical practice are different from those in clinical trials, and outcomes 
      may differ in different geographical settings. OBJECTIVES: To analyse the 
      efficacy, retention of treatment and adverse events in a cohort of such patients 
      at a referral centre in Barcelona, Spain. METHODS: Data from a cohort of 119 
      consecutive patients treated between January 2008 and March 2013 were 
      retrospectively collected. Drug survival was analysed by the Kaplan-Meier method 
      with log-rank test and Cox regression. RESULTS: The mean duration of treatment 
      was 25 months (median 22, range 2-60). The 75% improvement in Psoriasis Area and 
      Severity Index (PASI 75) response rates at 16 weeks, 6 months and 1 year of 
      treatment were 64%, 58% and 53%, respectively (intention-to-treat analysis). The 
      corresponding PASI 90 values were 49%, 52% and 50%. Biologic-naive patients (41%) 
      had significantly higher PASI 75 and PASI 90 response rates at 6 months and 1 
      year. On multivariate analysis, only PASI 90 response at 6 months was 
      significantly associated with treatment retention (P = 0.0009), with a hazard 
      ratio of 7.3 (95% confidence interval 2.3-23.6). Forty-eight adverse events (AEs) 
      occurred in 29 patients, and were serious in eight (0.032 events per 
      patient-year). Paradoxical flares of psoriasis or arthritis were seen in five 
      patients. Infections accounted for seven serious AEs, and were the reason for 
      discontinuation in two patients. CONCLUSIONS: PASI 90 response at 6 months was 
      the only independent variable predicting drug survival on multivariate analysis. 
      Infections, including de novo infection by Mycobacterium tuberculosis, accounted 
      for seven serious AEs.
CI  - (c) 2013 British Association of Dermatologists.
FAU - Lopez-Ferrer, A
AU  - Lopez-Ferrer A
AD  - Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat 
      Autonoma de Barcelona, Sant Antoni Maria Claret 167, 08025, Barcelona, Catalonia, 
      Spain.
FAU - Vilarrasa, E
AU  - Vilarrasa E
FAU - Gich, I J
AU  - Gich IJ
FAU - Puig, L
AU  - Puig L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Dermatologic Agents)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Dermatologic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2013/08/06 06:00
MHDA- 2014/07/17 06:00
CRDT- 2013/08/06 06:00
PHST- 2013/07/21 00:00 [accepted]
PHST- 2013/08/06 06:00 [entrez]
PHST- 2013/08/06 06:00 [pubmed]
PHST- 2014/07/17 06:00 [medline]
AID - 10.1111/bjd.12543 [doi]
PST - ppublish
SO  - Br J Dermatol. 2013 Nov;169(5):1141-7. doi: 10.1111/bjd.12543.